Objective To examine the potential impact of combining maternal age with fetal nuchal translucency thickness and maternal serum free β-human chorionic gonadotropin (β-hCG) 
INTRODUCTION
Prenatal screening for trisomy 21 based on the analysis of biochemical markers in maternal serum during the second trimester of pregnancy has become an established part of obstetric practice in many countries 1, 2 . A combination of maternal age with serum α-fetoprotein and free β-human chorionic gonadotropin (β-hCG) or maternal age with serum α-fetoprotein, total hCG and unconjugated estriol can identify approximately 65% of affected pregnancies for a 5% false-positive rate [3] [4] [5] [6] . Recent interest in prenatal screening for trisomy 21 has focused on the first trimester. Of the biochemical markers that have been investigated, only free β-hCG 7, 8 and pregnancy-associated plasma protein-A (PAPP-A) have been shown to be of any value 9, 10 . Several retrospective studies have estimated that the detection rate for pregnancies with Down's syndrome, by a combination of maternal age with serum free β-hCG and PAPP-A, would be around 60-65% for a 5% false-positive rate 10 . In terms of sonographic markers, in the early 1990s several reports of small series in high-risk pregnancies demonstrated a possible association between an increase in fetal nuchal translucency (NT) thickness at 10-14 weeks of gestation and the presence of a chromosomal defect 11 . A recent multicenter study involving 100 000 pregnancies has demonstrated that, in 72% of the trisomy 21 pregnancies, fetal NT thickness was above the 95th centile of the normal range, and screening by a combination of maternal age with fetal NT identified 77% of affected pregnancies, for a false-positive rate of 5% 12 .
In this retrospective study of 210 cases of trisomy 21 and 946 controls, we examine the potential impact of combining fetal NT with maternal free β-hCG and PAPP-A in screening at 10-14 weeks. With the availability of new immunodiagnostic technology based on timeresolved cryptate emission 13 , it has now become possible to obtain reproducible measurements of free β-hCG and PAPP-A within 30 min of taking a blood sample. It is therefore possible to combine the information from the ultrasound scan and maternal blood in the same clinical visit, so that parents can receive counselling concerning their combined estimated risk for an affected pregnancy.
METHODS
The study population was derived from two groups of women. The first comprised women with singleton pregnancies who were referred to the Harris Birthright Research Centre for Fetal Medicine for fetal karyotyping, because screening by a combination of maternal age and fetal NT at 10-14 weeks in their hospital identified these patients as being at high risk for Down's syndrome 12 . The second group comprised self-referred women for assessment of risk. Blood samples were collected from women at the time of the scan and the serum was aliquoted and stored at −20°C prior to blinded retrospective analysis. Gestational age was determined by measurement of fetal crown-rump length (CRL). Pregnancy outcome was ascertained in all women.
Serum samples from 210 pregnancies affected by trisomy 21 were available for biochemical analysis. A control group of 946 cases was selected from pregnancies resulting in the birth of an unaffected baby; these samples were collected within the same time scale as the affected group, and they were matched for the gestational age and maternal age distribution of the trisomy 21 group.
Maternal serum free β-hCG and PAPP-A were measured over a period of 5 days on the Kryptor analyzer -a random access immunoassay analyzer using time-resolved amplified cryptate emission (TRACE) technology -and the CIS automated immunofluorescent assays (CIS UK Ltd., High Wycombe, Bucks, UK). The between-day precision of these assays (coefficient of variation; CV) was 2.8% for PAPP-A at 1.68 mIU/ml and 3.2% for free β-hCG at 21.2 ng/ml.
Statistical analysis
Regression analysis was carried out to derive the relation between free β-hCG and PAPP-A in MoM with gestational age. Correction of each MoM for maternal weight was also performed using the reciprocal-linear regression weight correction procedure of Neveux and co-workers 14 . Assessment of the performance of various marker combinations as potential screening procedures was examined using standard statistical modelling techniques 15 . We used the measured parameters (corrected for maternal weight) for PAPP-A and free β-hCG and the reported parameters for nuchal translucency from 95 476 normal and 326 trisomy 21 pregnancies 12, 16 . Using these population parameters, a series of 15 000 random MoM values were selected for each marker from within the distributions of the affected and unaffected pregnancies. These values were used to calculate likelihood ratios 17 for the various marker combinations. The likelihood ratios were then used together with the age-related risk for trisomy 21 in the first trimester 18 to calculate the expected detection rate of affected pregnancies, at a fixed false-positive rate, in a population with the maternal age distribution of pregnancies in England and Wales
19
.
RESULTS
The characteristics of the trisomy 21 and control pregnancies are shown in Table 1 and the observed and regressed median values for free β-hCG and PAPP-A are shown in Table 2 . Free β-hCG MoM and PAPP-A MoM both in the trisomy 21 and the control groups fitted a Gaussian distribution after log10 transformation, with KolomogorovSmirnov and Anderson Darling tests showing linearity at the 0.01 probability level. Similarly, NT MoM in both trisomy 21 and unaffected cases were previously shown to fit a Gaussian distribution after log10 transformation 16 . In order to be combined directly with maternal age in a multivariate risk algorithm, each marker must be independent of maternal age. There was no significant correlation between maternal age in either the control or the trisomy 21 pregnancies for PAPP-A (r = 0.036 and r = 0.103, respectively), for free β-hCG (r = 0.036 and r = −0.092, respectively) or for NT thickness (r = −0.010 and r = −0.125, respectively). Table 3 summarizes the statistical parameters associated with the distributions of the biochemical markers, along with those established for NT 16 . Table 4 shows the distribution of analyte levels in the control group with various maternal weight bands. Each
Trisomy 21
(n = 210) marker showed a small but significant negative correlation with maternal weight (PAPP-A, r = −0.278; free β-hCG, r = −0.146). Using the procedure of Neveux and colleagues 14 to derive a correction factor for varying maternal weight and applying this to the study populations resulted in a slight tightening of the distributions; the SD for free β-hCG in the controls was 0.249 and in the trisomy 21 group was 0.271 and the respective values for PAPP-A were 0.237 and 0.275. When individual marker levels (as MoM) were compared against each other, there was no significant correlation between NT (as MoM) either in the control or in the trisomy 21 pregnancies for PAPP-A (r = 0.000 and r = −0.089, respectively) and free β-hCG (r = −0.057 and r = 0.000, respectively). There was a small but significant correlation between free β-hCG in MoM and PAPP-A in MoM (controls, r = 0.160; trisomy 21, r = 0.216).
In the 210 trisomy 21 pregnancies, free β-hCG was above the 95th centile of the controls in 70 (33%) cases and PAPP-A was below the 5th centile in 79 (38%) cases. When the observed statistical parameters were used in the mathematical model of a population with the maternal age distribution of pregnancies in England and Wales, the estimated detection rates using various marker combinations with maternal age at a fixed false-positive rate of 5% varied from 46% with maternal age and free β-hCG to 89% with maternal age and all three markers (Table 5) . Alternatively, at a fixed detection rate of 70%, the falsepositive rate varied from 6% with maternal age, free β-hCG and PAPP-A to 1% with maternal age, fetal NT, free β-hCG and PAPP-A (Table 6) .
DISCUSSION
This study has demonstrated the potential value of screening for trisomy 21 at 10-14 weeks of gestation by a combination of maternal age, fetal NT and maternal serum free β-hCG and PAPP-A; for a 5% invasive testing rate, about 90% of trisomy 21 pregnancies can be identified. Alternatively, at a fixed detection rate of 70%, the falsepositive rate would be 1%. Maternal serum free β-hCG in trisomy 21 pregnancies was increased. The median value was 2.15 MoM (95% CI, 1.94-2.33), which is compatible with the results of previous smaller series that also measured free β-hCG in the first trimester (Table 7) . However, the value is lower than in affected cases in the second trimester; in a large series of 480 trisomy 21 cases, the median MoM was 2.64 5 . The increase with gestation in the difference between trisomy 21 and normal pregnancies has also been shown in studies of paired samples from trisomy 21 pregnancies collected in the first and second trimesters 33 . In our study, there was an increasing trend in values with gestation (Figure 1) , even within the narrow range of 11-13 weeks, although this was not statistically significant. This may offer an explanation for the difference between our overall median of 2.15 and the 1.75 reported in a previous study 10 , in which more than 60% of the cases were prior to 11 weeks of gestation. The standard deviation in both the control and the trisomy 21 populations was tighter than that of previous studies 10, 33, 36 and this may reflect better assay precision and also a tighter distribution of gestational ages in our study population. At a 5% false-positive rate, the detection rate using free β-hCG alone was 33% and, in combination with maternal age, detection increased to 46%; these findings are similar to those of previous reports [27] [28] [29] [30] 32, 33, 35, 37 . Maternal serum PAPP-A in trisomy 21 pregnancies was decreased. The median value was 0.51 MoM (95% CI, 0.44-0.56), which is compatible with the results of
Number of cases Median MoM

Weeks' gestation (median and range)
Studies with median gestation < 11 weeks Ozturk, 1990 20 Spencer, 1992 7 Macintosh, 1994 24 Brambati, 1994 25 Biagiotti, 1995 28 Wald Table 7 Median multiples of the median (MoM) in published studies of free β-human chorionic gonadotropin (β-hCG) in trisomy 21 cases 
Number of cases Median MoM
Weeks' gestation (median and range)
Studies with median gestation < 11 weeks Brambati, 1993 38 Hurley, 1993 39 Macintosh, 1994 24 Brambati, 1994 25 Bersinger, 1994 40 Wald, 1996 
Studies with median gestation ≥ 11 weeks
Muller, 1993 41 Spencer, 1994 37 Brizot, 1994 42 Bersinger, 1994 40 Casals, 1996 43 Krantz, 1996 30 Berry, 1997 33 Haddow previous smaller series that also measured PAPP-A in the first trimester (Table 8) . The difference in PAPP-A between trisomy 21 and normal pregnancies decreases with advancing gestation and this may account for the variation in the reported median MoM between the various studies, because there was a considerable variation in the gestational age range of the populations that were examined. In our study, there was a significant trend in values even across the narrow gestational age range of 11-13 weeks (Figure 2) . Consequently, population parameters derived from studies using a wide gestational age range will not be appropriate if screening is to be focused at the optimal time for nuchal translucency measurement (10-14 weeks) 45 . The standard deviation in both the control and the trisomy 21 populations was tighter than that of previous studies and this may reflect the narrower gestational range of our population, compared to previous reports. At a 5% false-positive rate, the detection rate using PAPP-A alone was 38% and, in combination with maternal age, detection increased to 48%; these findings are remarkably similar to these of previous reports, despite differences in median MoM and standard deviation in the various studies 30, 33, 36, 42 . The observed variability of detection rate with the biochemical markers across the narrow gestational window makes it clear that risk algorithms will need to be designed with different statistical models for possibly each week of gestation across the first trimester, as we have suggested previously 45 . When consideration is given to combining biochemical markers together, it is necessary to take into account the degree of correlation between the markers. In the major published series 10, 30, 33, 36 , the correlations varied between −0.223 and 0.065 for the trisomy 21 pregnancies, and between −0.086 and 0.154 in the normal group; in our study, the correlations were 0.216 and 0.160, respectively. Combining free β-hCG and PAPP-A with maternal age in our study produced a modelled detection rate of 67% at a 5% false-positive rate; the estimated detection in previous studies was 55-63% 10, 30, 33, 34, 36, 46 . When biochemistry is combined with nuchal translucency, a further level of correlation needs to be taken into account. Our findings confirm the previous studies of Brizot and colleagues 27, 42 , indicating insignificant correlation of both PAPP-A and free β-hCG with nuchal translucency. Our estimated sensitivity of 89% for a 5% false-positive rate in screening by a combination of maternal age, maternal serum free β-hCG and PAPP-A and fetal nuchal translucency was similar to the estimate of 87% by Cuckle 47 and the 87% observed by Orlandi and co-workers 46 , and considerably better than the 80% estimated by Wald and Hackshaw 48 . Combining biochemistry with NT increases the modelled detection rate by a further 16% over and above that observed with NT and age alone.
Dunstan and Nix 49 have provided a methodology to compare detection rates between the first and second trimesters, taking into account fetal loss rates. Essentially, for the first-trimester test to be considered superior to that in the second trimester, the detection rate should be at least 8.3% higher. Clearly, if this is the case, first-trimester biochemistry alone (detection of 67%) would not be better than second-trimester biochemistry (detection of 65%), but the combination of NT and biochemistry in the first trimester (89%) is considerably more sensitive than biochemical screening in the second trimester.
The new technology for biochemical analysis, which provides automated, precise and reproducible measurements within 30 min of obtaining a blood sample, makes it possible to combine biochemical and ultrasonographic testing as well as counselling in one-stop clinics for early fetal assessment. Such interdisciplinary clinics would have the advantage of providing a more efficient service, bringing the benefit of improved sensitivity over previous methods of screening as well as the ability to deliver this quickly, so that patient anxiety and stress may be reduced. 
